Detailansicht

Wissensnetz

Person

Marc Suárez-Calvet

Neurologe

Name	Marc Suárez-Calvet
Zeit	2008- (Wirkungsdaten)
Ort	Spanien
Geschlecht	männlich
Akademischer Grad bzw. Titel	Dr.
Beruf	Neurologe (charakteristischer Beruf)
Variante	Marc Suarez-Calvet
Datensatztyp	Person
GND-Nummer	1275962610
Datensatz-ID	1275962610
Beteiligt an alle anzeigen Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology Reply to: Challenges to identifying risk versus protective factors in Alzheimer’s disease Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease APOE -ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid? Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-ε4 in middle-age cognitively unimpaired individuals from the ALFA study Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers Spatial patterns of white matter hyperintensities associated with Alzheimer’s disease risk factors in a cognitively healthy middle-aged cohort Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker? Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM 2, neurodegeneration and cognitive decline The FTD ‐like syndrome causing TREM 2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Marc Suárez-Calvet

Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology

Reply to: Challenges to identifying risk versus protective factors in Alzheimer’s disease

Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease

Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease

APOE -ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease

Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease

Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-ε4 in middle-age cognitively unimpaired individuals from the ALFA study

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers

Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals

The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers

Spatial patterns of white matter hyperintensities associated with Alzheimer’s disease risk factors in a cognitively healthy middle-aged cohort

Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease

Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker?

Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM 2, neurodegeneration and cognitive decline

The FTD ‐like syndrome causing TREM 2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism

Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS

sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers